(Total Views: 720)
Posted On: 05/12/2020 8:26:50 AM
Post# of 158227
I’m a little confused by the following
Quote: The initial Phase 2 clinical trial, which began in April locally, involved a randomized, double blind, placebo-controlled study to evaluate the use of leronlimab in patients with mild- to moderate-documented COVID-19 illness.
(snip)
A Phase 2 trial is designed to evaluate the drug’s effectiveness in people with the disease or condition being studied, and to determine the common short-term adverse effects and risks associated with the drug. A total of 54 patients were treated with leronlimab in that phase.
Did they already treat 54 patients in the mild/moderate trial? Or, did the reporter possibly get confused with the EIND numbers?
Quote: The initial Phase 2 clinical trial, which began in April locally, involved a randomized, double blind, placebo-controlled study to evaluate the use of leronlimab in patients with mild- to moderate-documented COVID-19 illness.
(snip)
A Phase 2 trial is designed to evaluate the drug’s effectiveness in people with the disease or condition being studied, and to determine the common short-term adverse effects and risks associated with the drug. A total of 54 patients were treated with leronlimab in that phase.
Did they already treat 54 patients in the mild/moderate trial? Or, did the reporter possibly get confused with the EIND numbers?
(0)
(0)
